Efficacy and safety of [11C]BIIB021 as a PET imaging ligand for molecular chaperone in the brain (801H)

未提供0 个研究点目标入组 20 人开始时间: 2025年2月4日最近更新: 2025年2月10日

试验速览

暂无简介。

•A person whose age is 20 years or older but under 40 at the time of obtaining consent. Gender does not matter.
•A person who applies voluntarily and is judged by the principal investigator or co-investigator to be capable of understanding the content of the explanatory document.

•A person who has a disease or medical history that is judged by the investigators to affect the PET scan.
•A person who, during a head MRI scan, is found to have findings suspected of affecting the PET scan (such as a history of clear cerebral infarction or cerebral hemorrhage).
•A person who exhibits obvious abnormalities in the physical examination, blood/urine tests, or cognitive function tests (only for step 2) during eligibility evaluation, and is judged by the investigator(s) to either affect the PET scan or be at a higher-than-usual risk of health harm from undergoing the PET scan.
•A person who is judged to be unable to remain still during the examination.
•A person with internal magnetic metal (including tattoos, cosmetic tattoos, pacemakers, etc.).
•A person with severe claustrophobia.
•A person with a history of drug allergies.
•A person who is pregnant, may be pregnant, or is currently breastfeeding.
•A person who participated in another interventional clinical study and received the intervention within one year prior to the time of obtaining consent.
•Any other person judged by the investigators to be unsuitable as a subject for this study.

发起方

未提供